Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday

Longeveron (NASDAQ:LGVN) will likely be posting its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect Longeveron to post earnings of ($0.42) per share and revenue of $0.11 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Longeveron Trading Up 2.8%

Shares of LGVN stock opened at $0.58 on Wednesday. The stock has a market cap of $12.40 million, a P/E ratio of -0.55 and a beta of 0.21. Longeveron has a 1 year low of $0.49 and a 1 year high of $1.92. The stock has a 50 day simple moving average of $0.56 and a 200 day simple moving average of $0.69.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.01% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $6.50.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.